Interstitial lung disease in gefitinib-treated Japanese patients with non-small-cell lung cancer: Genome-wide analysis of genetic data

Pharmacogenomics

Volumn 12, Issue 7, 2011, Pages 965-975

  Nyberg, Fredrik ^a,b   Barratt, Bryan J ^c   Mushiroda, Taisei ^d   Takahashi, Atsushi ^d   Jawaid, Ansar ^c   Hada, Shuji ^c   Umemura, Takaaki ^c   Fukuoka, Masahiro ^e   Nakata, Koichiro ^f   Ohe, Yuichiro ^g   Kato, Harubumi ^h,i   Kudoh, Shoji ^j,k   March, Ruth ^c   Nakamura, Yusuke ^l   Kamatani, Naoyuki ^d  

^a ASTRAZENECA R AND D   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c ASTRAZENECA   (United Kingdom)

^d INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f Nakata Clinic   (Japan)

^g NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^h TOKYO MEDICAL UNIVERSITY   (Japan)

ⁱ Niiza Shiki Central General Hospital   (Japan)

^j Japan Anti Tuberculosis Association   (Japan)

^k NIPPON MEDICAL SCHOOL   (Japan)

^l UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

gefitinib; genome wide association; interstitial lung disease; non small cell lung cancer; pharmacogenomics

Indexed keywords

GEFITINIB;

ACUTE INTERSTITIAL LUNG DISEASE; CASE CONTROL STUDY; CCDC122 GENE; CCT3 GENE; CHROMOSOME 1; CHROMOSOME 11; CHROMOSOME 13; CHROMOSOME 2; CHROMOSOME 3; CHROMOSOME 5; CLINICAL CLASSIFICATION; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE SEVERITY; ENC1 GENE; GENE; GENE FREQUENCY; GENE INTERACTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HEART DISEASE; HUMAN; INTERSTITIAL LUNG DISEASE; INTRON; JAPANESE; LUNG NON SMALL CELL CANCER; MAGI1 GENE; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY; RNF26 GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SMG5 GENE; SMOKING; STK39 GENE; WHO PERFORMANCE STATUS; ZBTB40 GENE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; JAPAN; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; QUINAZOLINES; RETROSPECTIVE STUDIES;

EID: 79960804673     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.38     Document Type: Conference Paper

References (9)

1. Inoue A, Saijo Y, Maemondo M et al. Severe acute interstitial pneumonia and gefitinib. Lancet 361(9373), 137-139 (2003). (Pubitemid 36092019)
2. Takano T, Ohe Y, Kusumoto M et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 45(1), 93-104 (2004). (Pubitemid 38757837)
3. American Thoracic Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS) and the European Respiratory Society (ERS) was adopted by the ATS Board of Directors, June 2001 and by The ERS Executive Committee, June 2001. Am. J. Respir. Crit. Care Med. 165(2), 277-304 (2002).
4. Abid SH, Malhotra V, Perry MC. Radiation-induced and chemotherapy-induced pulmonary injury. Curr. Opin. Oncol. 13(4), 242-248 (2001). (Pubitemid 32578989)
5. Raghu G, Nyberg F, Morgan G. The epidemiology of interstitial lung disease and its association with lung cancer. Br. J. Cancer 91(Suppl. 2), S3-S10 (2004). (Pubitemid 39334843)
6. Kudoh S, Kato H, Nishiwaki Y et al. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am. J. Respir. Crit. Care Med. 177(12), 1348-1357 (2008). (Pubitemid 351860912)
7. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc. Natl Acad. Sci. USA 100(16), 9440-9445 (2003). (Pubitemid 37033947)
8. Wijnen PA, Drent M, Nelemans PJ et al. Role of cytochrome P450 polymorphisms in the development of pulmonary drug toxicity: a case-control study in The Netherlands. Drug Saf. 31(12), 1125-1134 (2008).
9. Ando M, Okamoto I, Yamamoto N et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small cell lung cancer patients treated with gefitinib. J. Clin. Oncol. 24(16), 2549-2556 (2006). (Pubitemid 46630633)